Abstract Psychological symptoms were assessed over two years in a randomised trial ofthree forms of treatment given to women after mastectomy for stage II breast cancer. The treatments were: three weeks' radiotherapy; one year's adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil; and radiotherapy followed by chemotherapy. Analysis of the results on an intention to treat basis showed no substantial differences in depression or anxiety among groups at one, three, or six months after the operation. At 13 months, however, patients who had been allocated chemotherapy had significantly more symptoms, especially depression, than control patients treated with radiotherapy alone. Conditioned reflex nausea and vomiting increased considerably during the second six months of chemotherapy and persisted for up to a year afterwards.
Introduction
Anxiety and depression are common after mastectomy for breast cancer. ' Mutilating surgery contributes to this morbidity,2 and in addition the patient has to cope with the suspicion that she has an incurable disease. A recent analysis of 10 000 patients showed that adjuvant chemotherapy reduced the number of early deaths in postmenopausal women by about one sixth and in premenopausal women by about one third.I On this basis adjuvant chemotherapy is likely to be used more widely.
Although the extent of physical toxicity associated with the use of adjuvant chemotherapy is well documented, less attention has been paid to the incidence of psychological morbidity.4 I We report the results of a detailed evaluation of the morbidity associated with adjuvant chemotherapy.
Patients and methods
Consecutive patients aged under 70 with histologically proved stage II breast cancer were studied over five years. Within the framework of an existing trial of adjuvant chemotherapy after simple mastectomy patients were randomised to receive: (a) conventional postoperative orthovoltage radiotherapy (15 fractions over three weeks) to chest wall, axilla, infraclavicular and supraclavicular fossas, and internal mammary region (average tumour dose 37-8 Gy (3780 rads)); (b) chemotherapy alone; or (c) radiotherapy followed by chemotherapy.
The chemotherapy regimen was based on that described by Bonadonna et al except that all drugs were administered intravenously.6 Cyclophosphamide (300 mg/m2), methotrexate (40 mg/m2), and 5-fluorouracil (600 mg/m2) were administered on an outpatient basis on days 1 and 8 of consecutive 28 day cycles. Treatment was started within six weeks of mastectomy and continued until recurrence of disease or for one year. Patients allocated to combined radiotherapy and chemotherapy began their course of radiotherapy four to six weeks after the operation; chemotherapy was started four to six weeks after radiotherapy had been completed.
Psychological morbidity was measured with observer rating scales of depression and anxiety (0=absent, =mild, 2 =moderate, 3 =severe) developed by Maguire et al to study a postmastectomy population.7 The Leeds general scales for the self assessment of depression and anxiety and the general health questionnaire were also used.8 9 The Leeds scales were modified slightly to cover the same period as the general health questionnaire and observer scales-namely, the previous few weeks. Scores on the Leeds scales range from 0 to 18, and scores of seven or above indicate a high probability of clinical depression or anxiety.
Scores on the general health questionnaire range from 0 to 60. The usual threshold for probable psychiatric illness is a score of 12 or above, but the questionnaire contains somatic items such as lack of energy, which might be endorsed by patients with purely physical distress. The severe depression subscale of the questionnaire, which contains specific psychic items such as ideas of suicide, worthlessness, and hopelessness, was therefore analysed separately. Scores on this subscale range from 0 to 21, but there is no recognised threshold score. To determine such a threshold scores obtained a year after mastectomy from an earlier cohort of 44 patients participating in the same chemotherapy trial were examined. With a Maguire depression observer rating of two or above as the criterion for psychological morbidity scores of three or above on the severe depression subscale gave satisfactory discrimination between cases and non-cases. Six of eight cases and 32 of 36 non-cases were correctly classified-that is, the sensitivity was 75% and the specificity 89%.
A simple arbitrary physical symptom score was devised based on the presence or absence of several key symptoms in the month before assessment. These included anorexia, nausea, vomiting, mucosal irritation, hair loss, complete alopecia, skin reaction, pain, and dyspnoea. One point was allotted for each symptom present. The presence of conditioned reflex symptoms was also noted.'
The figure shows the times of assessment, which allowed psychological and physical morbidity to be measured before treatment, after radiotherapy, during the course of chemotherapy, shortly before completion of chemotherapy, and five and 11 months after the completion of chemotherapy. Patients receiving chemotherapy were reviewed at the end of the "rest" period-that is, as close as possible to day 28 of each cycle, when physical toxicity was minimal. Patients receiving radiotherapy were interviewed two to three weeks after completion of treatment.
The analysis was performed on an intention to treat basis-that is, all patients were included in the analysis regardless of whether they had relapsed or failed to complete chemotherapy. Statistical The prevalence of psychological morbidity is shown in tables III and IV. The prevalences of anxiety and depression measured by Maguire's observer scales at one month after mastectomy in the group treated with radiotherapy alone were 33% and 38% respectively, both falling to 14% at one year. The prevalences of anxiety and depression in the two groups treated with chemotherapy were similar at one, three, and six months. At 13 months, however, both anxiety (p<005) and depression (p<O 1F) were significantly greater in these two groups.
At one month psychological morbidity was slightly more evident on all self rating scales in patients allocated to combined treatment. At 13 months both groups allocated to chemotherapy showed greater psychological morbidity compared with the control group treated with radiotherapy alone. This excess was significant on both the Leeds depression and severe depression scales (p<003).
During the second year the press alence of psychological morbidity decreased in both groups allocated to chemotherapy. In contrast, at 18 As a result of the high prevalence of morbidity reported in these studies, and the failure to show appreciable benefit in terms of survival, serious reservations have been expressed in the United Kingdom about the use of adjuvant chemotherapy.'2 16 In the United States, where adjuvant chemotherapy has been more widely adopted as routine treatment, the need for quantitative psychosocial studies has been emphasised recently.'7 The lack of controlled studies has presumably been because withholding adjuvant chemotherapy has been thought to be unethical. In an uncontrolled study Meyerowitz et al found that up to 40 of 50 patients (80%) receiving cyclophosphamide, methotrexate, and 5-fluorouracil for a year reported emotional distress." Follow up indicated that quality of life was often impaired for several months after treatment."9
The present study failed to show appreciable differences in anxiety or depression up to six months after mastectomy. By that time, however, patients receiving chemotherapy alone or in combination had suffered more physical and conditioned reflex symptoms than those allocated radiotherapy alone. Furthermore, patients receiving combined treatment were already almost unanimous in stating that chemotherapy was the more unpleasant treatment. By 13 months nearly all patients allocated radiotherapy alone seemed to have recovered emotionally while depression, -anxiety, and conditioned reflex symptoms had risen to a peak in both groups treated with chemotherapy. At 13 months about a quarter of the patients allocated chemotherapy alone or in combination showed evidence of clinical depression as judged by both the Leeds and severe depression scales. About one third had conditioned reflex vomiting.
During the second year those patients who had received radiotherapy alone and who remained free of disease seemed to fare well emotionally, unlike those who developed systemic disease. Anxiety and depression decreased in the groups allocated to chemotherapy; systemic relapse, a rare event in those groups, had no perceptible impact on morbidity. Depression and anxiety due to adjuvant chemotherapy may persist slightly after treatment has finished, and conditioned reflex symptoms undoubtedly do so. Such symptoms, however, are probably counterbalanced by the distress, both emotional and physical, associated with systemic relapse in patients treated with radiotherapy alone.
The results of this study therefore indicate that adjuvant chemotherapy has its main psychological impact during the second six months of intended treatment, but the period of observation was limited arbitrarily to two years. It is not absolutely certain that the psychological cost to the patient and her family over her lifetime due to adjuvant chemotherapy exceeds that due to radiotherapy alone. A large scale randomised study to answer this question has not been performed and would present formidable problems: detailed lifetime follow up would be necessary. 
Introduction
Britain has a higher mortality from chronic bronchitis than any other country in western Europe.' This cannot be explained by international differences in environmental influences such as cigarette smoking and atmospheric pollution, nor by differences in death certification practices.2 The excess of urban over rural mortality and morbidity from bronchitis, which is characteristic of Britain, is also unexplained. 3 Reid and others conjectured that respiratory disease in childhood was a cause of chronic bronchitis in later life." Recent findings have shown that bronchiolitis, bronchitis, and pneumonia in infancy lead to persisting damage to the airways during childhood, with cough, wheeze, bronchial reactivity, and impaired ventilatory function.7-'0 In the long term follow up of a national sample of British children MRC Environmental Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton S09 4XY D J P BARKER, PHD, FRcp, director and professor of clinical epidemiology C OSMOND, Pun, statistician Correspondence to: Professor Barker. born in 1946 young adults who had had one or more lower respiratory infections before 2 years of age had a higher prevalence of chronic cough." 12 There is, however, no direct evidence to link respiratory infection during childhood with clinically established chronic bronchitis in adult life.
We have examined the geographical relation between past infant death rates from lower respiratory tract infection and current adult mortality from chronic bronchitis in England and Wales. We have also analysed the time trends in mortality from chronic bronchitis over the past 40 years.
Methods
The Office of Population Censuses and Surveys made available extracts from all death certificates in England and Wales during 1959-78. Our previous analysis of these data in relation to past infant mortality was based on the 11 years 1968-78,3 the period covered by the eighth revision of the International Classification of Diseases (ICD). For this analysis we added data on four selected causes of death during 1959-67. Mortality rates at ages 35-74 years were calculated for each sex and each local authority area grouped according to boundaries before 1974. For 1%8-78 rates were based on data from the 1971 Census, while for 1959-67 data from the 1961 Census were used. Rates were expressed as standardised mortality ratios. We used published mortality rates'4 for 1941-80 to analyse the time trends of chronic bronchitis and emphysema (ICD codes 106 b,c, 113 (5th revision); 501-502, 527 (6th revision); 501-502, 527.1 (7th revision); 490-492 (8th and 9th revisions)).
In England and Wales numbers of infant deaths by specific cause were published only from 1921, and this analysis is based on the years 1921-5. We divided causes of infant deaths into five groups using Woolf's classification"-congenital, bronchitis and pneumonia, infectious diseases, diarrhoea, and others.
We compared adult mortality with infant mortality (1921-5) in the four main geographical groups used by the Registrar General since 191 1-that is, county boroughs (larger towns), London boroughs, urban areas (metropolitan boroughs and urban districts) within counties, and rural areas. These groups divide England and Wales into 212 local authority areas, comprising 80 county boroughs, 15 London boroughs, 59 urban areas, and 58 rural areas. 3 We used correlation coefficients, regression analysis, and scatter plots to examine the relation between different causes of adult and infant deaths. 
